I think you are ignoring the mans successes that Mann has had. In 1956, Mann founded Spectrolab, the first of his aerospace companies. While at Spectrolab, an electrooptical systems company, he also founded Heliotek, a semiconductor company, that became a major supplier of solar cells for spacecraft. Among other accomplishments during his tenure, Mann's companies provided the electric power for over 100 spacecraft and constructed one of the lunar experiments. Although he sold both companies to Textron in 1960 (merged into one, Spectrolab is now a subsidiary of Boeing Satellite Systems), he continued to manage them until 1972. After he left those companies to found Pacesetter Systems, which focused on cardiac pacemakers, he sold that company in 1985 and managed it until 1992. It is now a part of St. Jude Medical. Mann then went on to establish MiniMed (insulin pumps and continuous glucose devices, now owned by Medtronic)
The sell stops were cleaned out down to 14.05 this morning. Very healthy action of advancing then shaking out weak holders, stopping out shorts then luring them back in. Rinse, repeat...
Although devices are usually sold just once, EYES will have upgrades from time to time as the technology improves. So although it's a device (already approved, by the way) there will be multiple sales of upgrades on each device sold, which makes it better than your run-of-the-mill device company. I don't think the market has priced in this particular business model.
It has become the personal property of Bigs and Ex, or are they the same person as some speculate. Go over to Stock Twits or stay on Yahoo and go to Market Pulse. You'll get no new info here. Just the incessant ramblings of two old men without a life.
Both EX and Bigs are obsessive. Just look at this board littered by their trash.
Yes, considering. Now that the trial is paused it will give pause to those considering. It will kill any momentum in the trial.
A supposed former executive speaking derisively of ones he considers "lower" than himself. I wonder how you treated your supposed employees.
For once, I agree. If the was an adverse event, SSH would have reported it immediately. There is more damage done when those things are hidden.
And very necessary for the trials. Just look at OREX. Sure, their stock is soaring because of leaked data but how long can that last. The FDA publicly chastised them and the trial will have to be extended, not shortened (as is the case with the now shortened SSH trial).
Hmmm. They announced the presentation at the Cowen conference on the 24th of February. The next day they received the approval for interim analysis. Would seem that the cancellation has something to do with the approval.
It will be taken twice a day, hence great profits for Novartis. Can it be discontinued?? Probably has to be taken for the life of the patient like all good "blockbuster" drugs.